Ciltacabtagene autoleucel—a novel BCMA-directed CAR T-cell therapy in patients with relapsed or refractory multiple myeloma / 中国临床药理学与治疗学

ABSTRACT

On February 28, 2022，the U. S. Food and Drug Administration (FDA) approved Ciltacabtagene autoleucel (Cilta-cel) for the treatment of relapsed or refractory multiple myeloma (RRMM) in adults. Cilta-cel is the first FDA-approved cell therapy product in China and the second chimeric antigen receptor (CAR)-T cell immunotherapy to target the B cell maturation antigen (BCMA) approved by FDA around the world. Recent studies have found that patients with RRMM treated with Cilta-cel have an overall remission rate (ORR) of 97% and a 12-month progression-free rate of 77f; common adverse effects include neutropenia, thrombocytopenia, anemia, cytokine release syndrome (CRS), neurotoxicity and so on. In this article, we summarize the mechanism of drug action, indications, pharmacokinetics, clinical studies and adverse effects of Cilta-cel briefly.